ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS

Main Article Content

saveria capria
silvia maria trisolini
clara minotti
caterina stefanizzi
luisa cardarelli
Martina Canichella
claudio cartoni
daniela diverio
maria stefania de propris
marco mancini
alessandra micozzi
robin foà
giovanna meloni

Keywords

Leukemia, Gentuzumab Ozogamicin, Allogeneic stem cell transplantation

Abstract

Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation.

We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant.

Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.

Downloads

Download data is not yet available.
Abstract 993 | PDF Downloads 447 HTML Downloads 724 cover letter Downloads 0

Most read articles by the same author(s)

1 2 > >>